Genitourinary Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Genitourinary Cancer Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA8134/ InPACT	International Penile Advanced Cancer Trial (InPACT) Sponsored by The Institute of Cancer Research (UK/EU) on behalf of the International Rare Cancers Initiative in Penile Cancer UK Group, and the National Cancer Institute (US) Coordinated in the US by the ECOG-ACRIN Cancer Research Group	Curtis A. Pettaway, MD, US Co-Chair (Yu-Hui Chen, MPH, MS)	400 internationally	09/08/2017 in the U.S.	EA8134 Resources
EA8171	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer	Clare M. Tempany, MD, Chair Rajan Gupta, MD, Co-Chair (Jon Steingrimsson, PhD)	852	10/10/2018	EA8171 Resources
EA8183/ ERADICATE	A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)	Alicia K. Morgans, MD (Yu-Hui Chen, MPH)	810	11/09/2020	EA8183 Resources
EA8184	A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers	Nagi B. Kumar, PhD, Chair (Sandra Lee, ScD)	360	05/20/2021	EA8184 Resources
EA8185/ INSPIRE	Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)	Monika Joshi, MD, MRCP Abhishek A. Solanki, MD, Co-Chair (Maneka Puligandla, MS)	114	08/25/2020	EA8185 Resources
EA8191/ INDICATE	Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)	Neha Vapiwala, MD Steve Cho, MD, Co-Chair (Yu-Hui Chen, MS, MPH)	804	10/08/2020	EA8191 Resources
EA8192	Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy	Jean Hoffman-Censits, MD, Chair (Jun Yin, MPH)	249	05/06/2021	EA8192 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA8134/
InPACT International Penile Advanced Cancer Trial (InPACT)

Sponsored by The Institute of Cancer Research (UK/EU) on behalf of the International Rare Cancers Initiative in Penile Cancer UK Group, and the National Cancer Institute (US)

Coordinated in the US by the ECOG-ACRIN Cancer Research Group Curtis A. Pettaway, MD, US Co-Chair
(Yu-Hui Chen, MPH, MS) 400
internationally 09/08/2017
in the U.S. EA8134 Resources

EA8171 Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer Clare M. Tempany, MD, Chair
Rajan Gupta, MD, Co-Chair
(Jon Steingrimsson, PhD) 852 10/10/2018 EA8171 Resources

EA8183/
ERADICATE A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) Alicia K. Morgans, MD
(Yu-Hui Chen, MPH) 810 11/09/2020 EA8183 Resources

EA8184 A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers Nagi B. Kumar, PhD, Chair
(Sandra Lee, ScD) 360 05/20/2021 EA8184 Resources

EA8185/
INSPIRE Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE) Monika Joshi, MD, MRCP
Abhishek A. Solanki, MD, Co-Chair
(Maneka Puligandla, MS) 114 08/25/2020 EA8185 Resources

EA8191/
INDICATE Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) Neha Vapiwala, MD
Steve Cho, MD, Co-Chair
(Yu-Hui Chen, MS, MPH) 804 10/08/2020 EA8191 Resources

EA8192 Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy Jean Hoffman-Censits, MD, Chair
(Jun Yin, MPH) 249 05/06/2021 EA8192 Resources

Download